ArticleFrontiers in pharmacology2025
Pancreatitis associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) database.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Type 3 Autoimmune Pancreatitis: What Do We Know So Far?Digestive diseases and sciences · 2026Review
- The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice.Medical sciences (Basel, Switzerland) · 2026Review
- Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs)-related pancreatitis is a rare but serious immune-related adverse event (AEs). This study aimed to investigate the risk and profile of ICIs-related pancreatitis on a real world setting by analyzing the FDA Adverse Event Reporting System (FAERS) data. Methods: Data were extracted from the FAERS database from the first quarter of 2011 to the third quarter of 2024. Descriptive analysis was used to represent the clinical features, while reporting odds ratio (ROR), proportional reported ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multiple Gamma Poisson Shrinker (MGPS) were used for disproportionation analysis. The time to onset (TTO) was determined by calculating the interval between pancreatitis AEs and drug initiation time. Results: A total of 1166 cases with positive signals for ICIs-related pancreatitis were screened, involving atezolizumab, durvalumab, avelumab, tislelizumab, pembrolizumab, nivolumab and ipilimumab. There were significant differences in the distribution of gender, weight, age, reporter, reporting country among all ICIs ( Conclusion: ICIs may have a significant association with the occurrence of pancreatitis. In clinical applications, it is necessary to closely monitor the indicators related to pancreatitis in patients, such as abdominal pain, nausea, vomiting, elevated serum amylase or lipase, and take timely intervention measures to reduce the risk of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.